WO2011025785A1 - Methods for the prevention and treatment of cerebral ischemia - Google Patents

Methods for the prevention and treatment of cerebral ischemia Download PDF

Info

Publication number
WO2011025785A1
WO2011025785A1 PCT/US2010/046503 US2010046503W WO2011025785A1 WO 2011025785 A1 WO2011025785 A1 WO 2011025785A1 US 2010046503 W US2010046503 W US 2010046503W WO 2011025785 A1 WO2011025785 A1 WO 2011025785A1
Authority
WO
WIPO (PCT)
Prior art keywords
tocotrienol quinone
alpha
subject
cerebral
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/046503
Other languages
English (en)
French (fr)
Inventor
Guy M. Miller
Viktoria Kheifets
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Edison Phamaceuticals Inc
Original Assignee
Edison Phamaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edison Phamaceuticals Inc filed Critical Edison Phamaceuticals Inc
Priority to MX2012002374A priority Critical patent/MX337990B/es
Priority to JP2012526918A priority patent/JP5785546B2/ja
Priority to EA201200355A priority patent/EA028677B1/ru
Priority to DK10747777.0T priority patent/DK2470168T3/en
Priority to CN201080048363.2A priority patent/CN102647981B/zh
Priority to PL10747777T priority patent/PL2470168T3/pl
Priority to SI201031644T priority patent/SI2470168T1/en
Priority to CA2772294A priority patent/CA2772294C/en
Priority to ES10747777.0T priority patent/ES2663709T3/es
Priority to AU2010286704A priority patent/AU2010286704B2/en
Priority to NO10747777A priority patent/NO2470168T3/no
Priority to EP10747777.0A priority patent/EP2470168B1/en
Priority to BR112012004167A priority patent/BR112012004167A2/pt
Publication of WO2011025785A1 publication Critical patent/WO2011025785A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention provides methods for preventing a cerebral ischemic condition, in a mammalian subject in need of such prevention, comprising administering to the subject an effective amount of one or more compounds of Formula I, with the proviso that the subject has never been administered an effective amount of one or more compounds of Formula I.
  • the invention relates to compositions and methods comprising an effective amount of compounds of Formula I, wherein R 1 and R 2 are independently of each other (Ci-C 6 )alkoxy and R 3 is (CrC 6 )alkyl. In other embodiments, the invention relates to compositions and methods comprising an effective amount of compounds of Formula I, wherein R 1 , R 2 , and R 3 are independently of each other (Q-C ⁇ alkyl.
  • cytoprotective property or “cytoprotective activity” if administration of the agent reduces and/or ameliorates symptoms of a cerebral ischemic condition and/or injury suffered by cells, tissues, organs and/or organisms that is induced secondary to cerebral ischemia.
  • alpha-tocotrienol quinone alpha-tocotrienol quinone
  • compositions of the present invention may also be in the form of microparticles,
  • the hippocampus is a source of a relatively homogenous population of neurons with well-characterized properties typical of central nervous system (CNS) neurons in general. Pyramidal neurons, the principal cell type in the hippocampus, have been estimated to account for 85% to 90% of the total neuronal population (Banker et al., (1998) Culturing Nerve Cells, 2 nd edition, The MIT Press, Cambridge, Mass.). Also, the hippocampus exhibits a remarkable capacity for activity- dependent changes in synaptic function, such as long-term potentiation (Hawkins et al., (1993). Annu. Rev.
  • the desired number of viable cells is added to poly-D-lysine-coated 12- well plates, flasks or MetTek culture dishes in Neurobasal/B27i, and incubated in air atmosphere with 5% CO 2 at 37°C.
  • the cells are generally seeded at a density of 1.5xlO 6 cells per T75 cm 2 flask and at a density of ca.100,000 cells per well of a 12- well plate.
  • Each T75 cm 2 flask received 15 mL of medium and each well of a 12- well plate received 1 mL of medium.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/US2010/046503 2009-08-26 2010-08-24 Methods for the prevention and treatment of cerebral ischemia Ceased WO2011025785A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
MX2012002374A MX337990B (es) 2009-08-26 2010-08-24 Metodos para la prevencion y tratamiento de isquemia cerebral.
JP2012526918A JP5785546B2 (ja) 2009-08-26 2010-08-24 脳虚血を予防または処置する方法
EA201200355A EA028677B1 (ru) 2009-08-26 2010-08-24 Способ лечения, предотвращения и/или улучшения нейронального повреждения, связанного с ишемией головного мозга
DK10747777.0T DK2470168T3 (en) 2009-08-26 2010-08-24 PROCEDURES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCAM
CN201080048363.2A CN102647981B (zh) 2009-08-26 2010-08-24 预防和治疗脑缺血的方法
PL10747777T PL2470168T3 (pl) 2009-08-26 2010-08-24 Sposoby zapobiegania i leczenia niedokrwienia mózgu
SI201031644T SI2470168T1 (en) 2009-08-26 2010-08-24 Procedures for the prevention and treatment of brain ischemia
CA2772294A CA2772294C (en) 2009-08-26 2010-08-24 Methods for the prevention and treatment of cerebral ischemia
ES10747777.0T ES2663709T3 (es) 2009-08-26 2010-08-24 Métodos para la prevención y el tratamiento de la isquemia cerebral
AU2010286704A AU2010286704B2 (en) 2009-08-26 2010-08-24 Methods for the prevention and treatment of cerebral ischemia
NO10747777A NO2470168T3 (https=) 2009-08-26 2010-08-24
EP10747777.0A EP2470168B1 (en) 2009-08-26 2010-08-24 Methods for the prevention and treatment of cerebral ischemia
BR112012004167A BR112012004167A2 (pt) 2009-08-26 2010-08-24 métodos para a prevenção e o tratamento de isquemia cerebral

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27526909P 2009-08-26 2009-08-26
US61/275,269 2009-08-26

Publications (1)

Publication Number Publication Date
WO2011025785A1 true WO2011025785A1 (en) 2011-03-03

Family

ID=42983642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/046503 Ceased WO2011025785A1 (en) 2009-08-26 2010-08-24 Methods for the prevention and treatment of cerebral ischemia

Country Status (17)

Country Link
US (3) US20110207828A1 (https=)
EP (1) EP2470168B1 (https=)
JP (2) JP5785546B2 (https=)
CN (1) CN102647981B (https=)
AU (1) AU2010286704B2 (https=)
BR (1) BR112012004167A2 (https=)
CA (1) CA2772294C (https=)
DK (1) DK2470168T3 (https=)
EA (1) EA028677B1 (https=)
ES (1) ES2663709T3 (https=)
HU (1) HUE037592T2 (https=)
MX (1) MX337990B (https=)
NO (1) NO2470168T3 (https=)
PL (1) PL2470168T3 (https=)
PT (1) PT2470168T (https=)
SI (1) SI2470168T1 (https=)
WO (1) WO2011025785A1 (https=)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2720689A4 (en) * 2011-06-14 2014-11-26 Edison Pharmaceuticals Inc CATECHOL DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH OXIDATIVE STRESS
KR20140138976A (ko) * 2012-03-19 2014-12-04 시다라 세라퓨틱스, 인코포레이티드 에키노칸딘 계열의 화합물에 대한 투여 용법
JP2015527400A (ja) * 2012-09-07 2015-09-17 エジソン ファーマシューティカルズ， インコーポレイテッド 個体のレドックス状態の調節において使用するためのキノン誘導体
AU2011245384B2 (en) * 2010-04-27 2016-02-18 Bioelectron Technology Corporation Formulations of quinones for the treatment of ophthalmic diseases
RU2578451C1 (ru) * 2014-12-09 2016-03-27 Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Амурская Государственная Медицинская Академия" Министерства Здравоохранения Российской Федерации Способ повышения устойчивости головного мозга к ишемии во время реконструктивных операций на брахиоцефальных артериях
US9370496B2 (en) 2009-04-28 2016-06-21 Edison Pharmaceuticals, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
US11197909B2 (en) 2017-07-12 2021-12-14 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
US11584728B2 (en) 2019-10-04 2023-02-21 Stealth Biotherapeutics Inc. Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia
US11712459B2 (en) 2016-03-16 2023-08-01 Cidara Therapeutics, Inc. Dosing regimens for treatment of fungal infections
US12037350B2 (en) 2020-04-03 2024-07-16 Stealth Biotherapeutics Inc. Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia
US12344680B2 (en) 2011-03-03 2025-07-01 Napp Pharmaceutical Group Limited Antifungal agents and uses thereof

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
EP2471530B1 (en) * 2005-06-01 2017-01-11 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US9278085B2 (en) 2006-02-22 2016-03-08 Edison Pharmaceuticals, Inc. Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
WO2009061744A2 (en) 2007-11-06 2009-05-14 Edison Pharmaceuticals, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
EA023618B1 (ru) * 2008-01-08 2016-06-30 Эдисон Фармасьютикалз, Инк. Производные (гет)арил-п-хинона для лечения митохондриальных болезней
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
WO2009158348A1 (en) * 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
EP2362726B1 (en) 2008-10-14 2018-08-08 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
CA2741767C (en) 2008-10-28 2017-09-12 Ptc Therapeutics, Inc. Process for the production of alpha-tocotrienol and derivatives
US20110172312A1 (en) * 2009-12-31 2011-07-14 Miller Guy M Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
JP2014520894A (ja) 2011-07-19 2014-08-25 エジソン ファーマシューティカルズ， インコーポレイテッド 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
GB201117808D0 (en) * 2011-10-14 2011-11-30 Siemens Medical Solutions SUV correction following dose infiltration
CN112451518B (zh) * 2012-11-13 2025-02-21 因维克特斯生物技术有限公司 生育三烯酚的经粘膜递送
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US10189830B2 (en) 2013-03-15 2019-01-29 Bioelectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
AU2015364640B2 (en) 2014-12-16 2020-08-13 Ptc Therapeutics, Inc. Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
EP3390377B1 (en) 2015-12-16 2026-03-25 PTC Therapeutics, Inc. Improved methods for enriching alpha-tocotrienol from mixed tocol compositions
WO2017106803A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
US10707531B1 (en) 2016-09-27 2020-07-07 New Dominion Enterprises Inc. All-inorganic solvents for electrolytes
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
BR112021000018A2 (pt) * 2018-07-03 2021-07-06 Venturis Therapeutics Inc composições e métodos para tratamento de acidente vascular cerebral
KR102337954B1 (ko) * 2018-08-16 2021-12-10 차의과학대학교 산학협력단 뇌졸중 치료용 조성물 및 이를 스크리닝하는 방법
KR20210076956A (ko) 2018-10-17 2021-06-24 피티씨 테라퓨틱스, 인크. α-시누클레인병증, 타우병증 및 기타 장애를 억제 및 치료하기 위한 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온
CN114729018A (zh) * 2019-10-17 2022-07-08 宾州研究基金会 再生功能神经元以治疗出血性中风
JP2023553728A (ja) * 2020-12-22 2023-12-25 コーニンクレッカ フィリップス エヌ ヴェ 血管狭窄の位置特定
CN113066113B (zh) * 2021-04-27 2022-01-11 河北医科大学第二医院 自发性高血压大鼠脑模板和地图集的构建方法及设备
PE20240893A1 (es) 2021-07-08 2024-04-24 Ptc Therapeutics Inc Composiciones farmaceuticas que comprenden 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5872108A (en) 1995-03-06 1999-02-16 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
WO1999025336A1 (en) 1997-11-17 1999-05-27 Lipogenics, Inc. Methods for preventing restenosis using tocotrienols
WO2000078296A2 (en) 1999-06-17 2000-12-28 Basf Aktiengesellschaft Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
WO2007100652A2 (en) * 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
WO2009111543A2 (en) * 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments with redox-active therapeutics
WO2010030607A1 (en) * 2008-09-10 2010-03-18 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
US20100105930A1 (en) 2008-10-28 2010-04-29 Wesson Kieron E Process for the production of alpha-tocotrienol and derivatives

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5938203B2 (ja) * 1976-04-26 1984-09-14 エーザイ株式会社 補酵素ｑを主成分とする脳循環障害治療剤
US6232060B1 (en) * 1996-01-19 2001-05-15 Galileo Laboratories, Inc. Assay system for anti-stress agents
US5801159A (en) * 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
FR2753098B1 (fr) * 1996-09-06 1998-11-27 Sod Conseils Rech Applic Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
US6426362B1 (en) * 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
US6528042B1 (en) * 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US6346544B2 (en) * 2000-03-02 2002-02-12 Oklahoma Medical Research Foundation Desmethyl tocopherols for protecting cardiovascular tissue
DE10034233A1 (de) * 2000-07-14 2002-01-24 Basf Ag Tocotrienolchinon-Cyclisierungsprodukte
WO2002047680A2 (en) * 2000-12-15 2002-06-20 Galileo Laboratories, Inc. Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
US7034054B2 (en) * 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
US6608196B2 (en) * 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
WO2003015494A2 (en) * 2001-08-21 2003-02-27 Galileo Pharmaceuticals, Inc. Tocopherol enriched compositions and amelioration of inflammatory symptoms
AU2002352726A1 (en) * 2001-11-15 2003-06-10 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
US20040152764A1 (en) * 2001-12-14 2004-08-05 Miller Guy M. Compositions and methods for the prevention and treatment of cerebral ischemia
US7078541B2 (en) * 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
US6653346B1 (en) * 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
JP4599292B2 (ja) * 2002-10-30 2010-12-15 エジソン ファーマシューティカルズ， インコーポレイテッド 物理的−化学的特性に基づく治療用化合物の同定
WO2005033092A1 (en) * 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
EP2471530B1 (en) * 2005-06-01 2017-01-11 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
CA2622523C (en) * 2005-09-15 2014-02-18 Edison Pharmaceuticals, Inc. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
WO2008086025A2 (en) * 2007-01-10 2008-07-17 Edison Pharmaceuticals, Inc. Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
WO2009061744A2 (en) * 2007-11-06 2009-05-14 Edison Pharmaceuticals, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
WO2009088572A2 (en) * 2008-01-07 2009-07-16 Centocor, Inc. Method of treating erythropoietin hyporesponsive anemias
EA023618B1 (ru) * 2008-01-08 2016-06-30 Эдисон Фармасьютикалз, Инк. Производные (гет)арил-п-хинона для лечения митохондриальных болезней
WO2009111576A2 (en) * 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
CA2723621A1 (en) * 2008-05-15 2009-11-19 Edison Pharmaceuticals, Inc Treatment of hearing and balance impairments using compounds having erythropoietin activity
WO2009143268A2 (en) * 2008-05-22 2009-11-26 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
WO2009158348A1 (en) * 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
WO2010005989A1 (en) * 2008-07-09 2010-01-14 Edison Pharmaceuticals, Inc. Dermatological compositions with anti-aging and skin even-toning properties
US20100029784A1 (en) * 2008-07-30 2010-02-04 Hinman Andrew W Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties
EP2362726B1 (en) * 2008-10-14 2018-08-08 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
JP2012525397A (ja) * 2009-04-28 2012-10-22 エジソン ファーマシューティカルズ， インコーポレイテッド 眼科疾患を治療するためのトコトリエノールキノンの製剤
EP2424360A4 (en) * 2009-04-28 2012-10-03 Ampere Life Sciences Inc TOPICAL, PERIOCULAR OR INTRAOCULAR USE OF TOCOTRIENOLS FOR THE TREATMENT OF OPHTHALMIC DISEASES
PL2424495T3 (pl) * 2009-04-28 2018-06-29 Bioelectron Technology Corporation Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu
EP2609921A1 (en) * 2009-06-25 2013-07-03 Ampere Life Sciences, Inc. Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts
US20110172312A1 (en) * 2009-12-31 2011-07-14 Miller Guy M Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
AU2011238525A1 (en) * 2010-04-06 2012-11-08 Edison Pharmaceuticals, Inc. Treatment of Ataxia Telangiectasia
CA2797581A1 (en) * 2010-04-27 2011-11-03 Edison Pharmaceuticals, Inc. Formulations of quinones for the treatment of ophthalmic diseases
US20120101169A1 (en) * 2010-07-14 2012-04-26 Penwest Pharmaceuticals Co. Methods of providing anticoagulation effects in subjects
WO2012068552A1 (en) * 2010-11-19 2012-05-24 Edison Pharmaceuticals, Inc. Methods for improving blood glucose control

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5872108A (en) 1995-03-06 1999-02-16 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
WO1999025336A1 (en) 1997-11-17 1999-05-27 Lipogenics, Inc. Methods for preventing restenosis using tocotrienols
WO2000078296A2 (en) 1999-06-17 2000-12-28 Basf Aktiengesellschaft Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
WO2007100652A2 (en) * 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
WO2009111543A2 (en) * 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments with redox-active therapeutics
WO2010030607A1 (en) * 2008-09-10 2010-03-18 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
US20100105930A1 (en) 2008-10-28 2010-04-29 Wesson Kieron E Process for the production of alpha-tocotrienol and derivatives

Non-Patent Citations (35)

* Cited by examiner, † Cited by third party
Title
"Coenzyme-Q used to treat headaches, dizziness etc.. administered orally or parenterally", WPI WORLD PATENT INFORMATION DERWENT, vol. 77, no. 50, 1977, XP002138662 *
"Methods in Cell Biology", vol. XIV, 1976, ACADEMIC PRESS, pages: 33
"Remington: The Science and Practice of Pharmacy, 20th edition", 2003, LIPPINCOTT WILLIAMS & WILKINS
"Remington's Pharmaceutical Sciences", 1991, MACK PUB. CO.
BANKER ET AL.: "Culturing Nerve Cells, 2dedition,", 1998, THE MIT PRESS
CHOI, NEURON, vol. 1, 1988, pages 623 - 634
DEARLING ET AL., J. BIOL. INORG. CHEM, vol. 7, 2002, pages 249 - 259
DIENER ET AL., STROKE, vol. 27, 1996, pages 76 - 81
DUONG, T. Q.; FISHER, M., CURR. ATHEROSCL. REP., vol. 6, 2004, pages 267 - 273
FLYNN ET AL.: "Basic Neurochemistry", 1989, RAVEN PRESS, article "Ischemia and Hypoxia", pages: 783 - 810
FUJIBAYASHI ET AL., J. NUCL. MED.(1997), vol. 38, no. 7, 1997, pages 1155 - 1160
FUJIBAYASHI ET AL.: "Copper-62 ATSM: a new hypoxia imaging agent with high membrane permeability low redox potential", J. NUCL. MED., vol. 38, 1997, pages 1155 - 1160
FUKUZAWA ET AL., LIPIDS, vol. 17, 1982, pages 511 - 13
GOLDBERG ET AL., STROKE, vol. 21, 1990, pages 75 - 77
GONZALEZ, MED. HYPOTHES., vol. 32, 1990, pages 107 - 110
GRAU ET AL., CHEM. PHYS. LIPIDS, vol. 91, 1998, pages 109 - 118
GROTTA ET AL., STROKE, vol. 19, 1988, pages 447 - 454
GUY W.: "Early clinical drug evaluation unit (ECDEU) assessment manual for psychopharmacology", 1976, pages: 217 - 222
HAWKINS ET AL., ANNU. REV. NEUROSCI., vol. 16, 1993, pages 625 - 665
IKAWA M. ET AL., MILOCHONDRION, vol. 9, 2009, pages 144 - 148
KANNO ET AL., FREE RADIC. RES., vol. 24, 1996, pages 181 - 189
KINOUCHI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 11158 - 11162
LEE, DIFFUSION-CONTROLLED MATRIX SYSTEMS, pages 155 - 198
LEWIS ET AL., J. NUCL. MED., vol. 42, 2001, pages 655 - 661
MACMANUS ET AL., NEUROSCI. LETT., vol. 164, 1993, pages 89 - 92
MOLINARI ET AL.: "Pathophysiology, Diagnosis and Management", vol. 1, 1986, CHURCHILL LIVINGSTONE, article "Experimental models of ischemic stroke", pages: 57 - 73
NEUZIL ET AL., CARD. DRUGS. THER., vol. 12, 1998, pages 421 - 423
OBATA ET AL., ANN. NUCL. MED., vol. 15, 2001, pages 499 - 504
PARK ET AL., NEUROCHEM, vol. 74, 2000, pages 114 - 124
RICCIARELLI ET AL., BIOCHEM. J., vol. 334, 1998, pages 243 - 249
RON; LANGER: "Treatise on Controlled Drug Delivery", 1992, MARCEL DEKKER, INC., article "Erodible Systems", pages: 199 - 224
SIESJO, J. CEREB. BLOOD FLOW METAB., vol. 1, 1981, pages 155 - 185
STROHSCHEIN ET AL., ANAL. CHEM., vol. 70, 1998, pages 13 - 18
STROKE, vol. 36, 2005, pages E144 - E 152
WATSON ET AL., ANN. NYACAD. SCI., vol. 59, 1988, pages 269 - 281

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9370496B2 (en) 2009-04-28 2016-06-21 Edison Pharmaceuticals, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
US10195161B2 (en) 2009-04-28 2019-02-05 Bioelectron Technology Corporation Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
AU2011245384B2 (en) * 2010-04-27 2016-02-18 Bioelectron Technology Corporation Formulations of quinones for the treatment of ophthalmic diseases
AU2011245384C1 (en) * 2010-04-27 2016-09-01 Bioelectron Technology Corporation Formulations of quinones for the treatment of ophthalmic diseases
US12344680B2 (en) 2011-03-03 2025-07-01 Napp Pharmaceutical Group Limited Antifungal agents and uses thereof
EP2720689A4 (en) * 2011-06-14 2014-11-26 Edison Pharmaceuticals Inc CATECHOL DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH OXIDATIVE STRESS
US11654196B2 (en) 2012-03-19 2023-05-23 Cidara Therapeutics, Inc. Dosing regimens for echinocandin class compounds
KR20140138976A (ko) * 2012-03-19 2014-12-04 시다라 세라퓨틱스, 인코포레이티드 에키노칸딘 계열의 화합물에 대한 투여 용법
KR102061486B1 (ko) 2012-03-19 2020-01-03 시다라 세라퓨틱스, 인코포레이티드 에키노칸딘 계열의 화합물에 대한 투여 용법
KR20200003423A (ko) * 2012-03-19 2020-01-09 시다라 세라퓨틱스, 인코포레이티드 에키노칸딘 계열의 화합물에 대한 투여 용법
KR102236462B1 (ko) 2012-03-19 2021-04-08 시다라 세라퓨틱스, 인코포레이티드 에키노칸딘 계열의 화합물에 대한 투여 용법
JP2015527400A (ja) * 2012-09-07 2015-09-17 エジソン ファーマシューティカルズ， インコーポレイテッド 個体のレドックス状態の調節において使用するためのキノン誘導体
RU2578451C1 (ru) * 2014-12-09 2016-03-27 Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Амурская Государственная Медицинская Академия" Министерства Здравоохранения Российской Федерации Способ повышения устойчивости головного мозга к ишемии во время реконструктивных операций на брахиоцефальных артериях
US11712459B2 (en) 2016-03-16 2023-08-01 Cidara Therapeutics, Inc. Dosing regimens for treatment of fungal infections
US11819533B2 (en) 2017-07-12 2023-11-21 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
US11197909B2 (en) 2017-07-12 2021-12-14 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
US11584728B2 (en) 2019-10-04 2023-02-21 Stealth Biotherapeutics Inc. Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia
US12049455B2 (en) 2019-10-04 2024-07-30 Stealth Biotherapeutics Inc. Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia
US12037350B2 (en) 2020-04-03 2024-07-16 Stealth Biotherapeutics Inc. Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia

Also Published As

Publication number Publication date
EP2470168B1 (en) 2018-01-31
JP5785546B2 (ja) 2015-09-30
SI2470168T1 (en) 2018-05-31
JP2013503168A (ja) 2013-01-31
AU2010286704A1 (en) 2012-03-22
PT2470168T (pt) 2018-03-28
AU2010286704B2 (en) 2016-10-20
US20170007553A1 (en) 2017-01-12
BR112012004167A2 (pt) 2016-03-29
CA2772294A1 (en) 2011-03-03
DK2470168T3 (en) 2018-05-07
CN102647981A (zh) 2012-08-22
NO2470168T3 (https=) 2018-06-30
EA028677B1 (ru) 2017-12-29
MX2012002374A (es) 2012-04-10
US20180344667A1 (en) 2018-12-06
US20110207828A1 (en) 2011-08-25
CA2772294C (en) 2018-08-21
MX337990B (es) 2016-03-30
JP2015091899A (ja) 2015-05-14
EA201200355A1 (ru) 2012-07-30
PL2470168T3 (pl) 2018-06-29
CN102647981B (zh) 2016-09-28
EP2470168A1 (en) 2012-07-04
ES2663709T3 (es) 2018-04-16
HUE037592T2 (hu) 2018-09-28

Similar Documents

Publication Publication Date Title
EP2470168B1 (en) Methods for the prevention and treatment of cerebral ischemia
US7034054B2 (en) Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
US20020132845A1 (en) Compositions and methods for the prevention and treatment of tissue ischemia
US20220395460A1 (en) Nutraceutical or pharmaceutical composition for use in the treatment of polycystic ovary syndrome or of diseases or disorders related thereto
WO2019098811A2 (ko) Chp(시클로-히스프로)를 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물
Sarwer-Foner Recognition and management of drug-induced extrapyramidal reactions and “paradoxical” behavioural reactions in psychiatry
Sun et al. kudiezi injection attenuates apoptosis and neuroinflammation for ameliorating angiogenesis via miR-21/PDCD4/NF-κB Axis in MCAO/Reperfusion rats
TW202203911A (zh) 細胞老化抑制用組成物及抑制細胞老化的方法
HK1171665A (en) Methods for the prevention and treatment of cerebral ischemia
HK1171665B (en) Methods for the prevention and treatment of cerebral ischemia
US11185553B2 (en) Pharmaceutical composition for preventing or treating ischemic-reperfusion injury comprising bile acids
US20040152764A1 (en) Compositions and methods for the prevention and treatment of cerebral ischemia
CN117298128A (zh) 熊果苷在制备防治肥胖的药物中应用
CN112807296A (zh) 琥珀酸在诊断或治疗自然流产中的应用
EP4338798A1 (en) Pharmaceutical preparation containing genistein for use in the prevention or treatment of glaucoma and/or ocular hypertension
CN115645431B (zh) 一种组合物及其应用
CN115581702A (zh) 芍药素-3-o-阿拉伯糖苷在制备药物或保健食品的应用
Ragan et al. Brain injury associated with chronic alcoholism
CN115645430A (zh) 飞燕草素-3-o-半乳糖苷在制备药物或保健食品的应用
HK40082585A (en) Composition for suppressing cellular senescence, and method for suppressing cellular senescence
KR20200126354A (ko) 진세노사이드 Rb2를 포함하는 신경세포 보호용 조성물
CN100493507C (zh) 化合物6-糠基氨基嘌呤制备抗雌性生殖器官损伤药物应用
CN114886889A (zh) 土木香内酯或其衍生物在制备用于预防或治疗肥胖的药物、保健品或食品中的用途
KR20200042745A (ko) 진세노사이드 Rb2를 포함하는 신경세포 보호용 조성물
Lloyd A quantitative estimation of the effect of rutin on the biological potency of vitamin C

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080048363.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10747777

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012526918

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2772294

Country of ref document: CA

Ref document number: MX/A/2012/002374

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010286704

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2010747777

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2010286704

Country of ref document: AU

Date of ref document: 20100824

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201200355

Country of ref document: EA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012004167

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012004167

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120224